Ascendis Pharma A/S
About Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $13.0B
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $13.0B
- Shares outstanding
- 63.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 20, 2026
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Trading 18% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Ascendis Pharma A/S.
Write a review
News about Ascendis Pharma A/S
News & sentiment via Polygon.io
